| 產(chǎn)品編號 | bs-0832R |
| 英文名稱 | Rabbit Anti-MICA antibody |
| 中文名稱 | MHC I類鏈相關(guān)蛋白A/組織相容性復合物MHCIa抗體 |
| 別 名 | MHC I a; MHC class I polypeptide-related sequence A; MHCA; MHC class-I chain related protein A; HLA class I antigen; FLJ36918; FLJ60820; MGC111087; MGC21250; MHC class I chain related gene A protein; MHC class I chain related protein A; MHC class I chain related protein A HLA B HLA C; MHC class I polypeptide related sequence A; MHC class I related protein; MIC A; PERB11.1; Stress inducible class I homolog; MICA_HUMAN; MIC A; MIC-A; micA. |
 |
Specific References (7) | bs-0832R has been referenced in 7 publications.
|
| 研究領(lǐng)域 | 腫瘤 細胞生物 免疫學 結(jié)合蛋白 |
| 抗體來源 | Rabbit |
| 克隆類型 | Polyclonal |
| 交叉反應(yīng) | Human,Mouse |
| 產(chǎn)品應(yīng)用 | WB=1:500-2000,IHC-P=1:100-500,IHC-F=1:100-500,IF=1:100-500,Flow-Cyt=1μg/Test
not yet tested in other applications. optimal dilutions/concentrations should be determined by the end user. |
| 理論分子量 | 43kDa |
| 細胞定位 | 細胞漿 細胞膜 |
| 性 狀 | Liquid |
| 濃 度 | 1mg/ml |
| 免 疫 原 | KLH conjugated synthetic peptide derived from human MICA: 101-200/383 |
| 亞 型 | IgG |
| 純化方法 | affinity purified by Protein A |
| 緩 沖 液 | 0.01M TBS (pH7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol. |
| 保存條件 | Shipped at 4℃. Store at -20℃ for one year. Avoid repeated freeze/thaw cycles. |
| 注意事項 | This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications. |
| PubMed | PubMed |
| 產(chǎn)品介紹 |
The MHC class I chain-related (MIC) proteins are related to the Major histocompatibility complex (MHC) class I proteins which are ubiquitously expressed and mediate the recognition of intracellular antigens by cytotoxic T cells. The MHC class I chain-related (MIC) proteins are recognized by NKG2D, a receptor on NK and T cells, and promote anti-tumor activity. MICA, a member of the MIC family, is widely expressed on many tumors, and it is the MICA/NKG2D interaction that is thought to stimulate the anti-tumor reactivity by T lymphocytes. MICA is present in virtually every tissue except the nervous system, suggesting that MIC protein expression may only be one component of the anti-tumor activity of the immune system. Function: Seems to have no role in antigen presentation. Acts as a stress-induced self-antigen that is recognized by gamma delta T-cells. Ligand for the KLRK1/NKG2D receptor. Binding to KLRK1 leads to cell lysis. Subcellular Location: Cell membrane. Cytoplasm. Expressed on the cell surface in gastric epithelium, endothelial cells and fibroblasts and in the cytoplasm in keratinocytes and monocytes. Infection with human adenovirus 5 suppresses cell surface expression due to the adenoviral E3-19K protein which causes retention in the endoplasmic reticulum. Tissue Specificity: Widely expressed with the exception of the central nervous system where it is absent. Expressed predominantly in gastric epithelium and also in monocytes, keratinocytes, endothelial cells, fibroblasts and in the outer layer of Hassal's corpuscles within the medulla of normal thymus. In skin, expressed mainly in the keratin layers, basal cells, ducts and follicles. Also expressed in many, but not all, epithelial tumors of lung, breast, kidney, ovary, prostate and colon. In thyomas, overexpressed in cortical and medullar epithelial cells. Tumors expressing MICA display increased levels of gamma delta T cells. Post-translational modifications: N-glycosylated. Glycosylation is not essential for interaction with KLRK1/NKG2D but enhances complex formation. Proteolytically cleaved and released from the cell surface of tumor cells which impairs KLRK1/NKG2D expression and T-cell activation. DISEASE: Note=Anti-MICA antibodies and ligand shedding are involved in the progression of monoclonal gammopathy of undetermined significance (MGUS)to multiple myeloma. Genetic variations in MICA may be a cause of susceptibility to psoriasis type 1 (PSORS1) [MIM:177900]. Psoriasis is a common, chronic inflammatory disease of the skin with multifactorial etiology. It is characterized by red, scaly plaques usually found on the scalp, elbows and knees. These lesions are caused by abnormal keratinocyte proliferation and infiltration of inflammatory cells into the dermis and epidermis. Genetic variation in MICA is a cause of susceptibility to psoriatic arthritis (PSORAS) [MIM:607507]. PSORAS is an inflammatory, seronegative arthritis associated with psoriasis. It is a heterogeneous disorder ranging from a mild, non-destructive disease to a severe, progressive, erosive arthropathy. Five types of psoriatic arthritis have been defined: asymmetrical oligoarthritis characterized by primary involvement of the small joints of the fingers or toes; asymmetrical arthritis which involves the joints of the extremities; symmetrical polyarthritis characterized by a rheumatoidlike pattern that can involve hands, wrists, ankles, and feet; arthritis mutilans, which is a rare but deforming and destructive condition; arthritis of the sacroiliac joints and spine (psoriatic spondylitis). Similarity: Belongs to the MHC class I family. MIC subfamily. Contains 1 Ig-like C1-type (immunoglobulin-like) domain. SWISS: Q29983 Gene ID: 100507436 Database links: Entrez Gene: 100507436 Human Entrez Gene: 4276 Human Omim: 600169 Human SwissProt: Q29983 Human Unigene: 130838 Human Unigene: 728757 Human MICA蛋白是一種細胞應(yīng)激分子，在正常組織中表達量少，僅在腸道上皮組織表達量稍高，但是在多種腫瘤細胞，尤其是上皮源性的腫瘤如肺癌、乳腺癌、腎癌、卵巢癌、結(jié)腸癌等細胞表面高表達，并在細胞發(fā)生癌變的早期階段出現(xiàn)在細胞表面。 該分子與相應(yīng)受體NKG2D結(jié)合后可激活NK細胞、Vd1 gd T細胞、CD8+ T細胞的細胞毒作用，從而產(chǎn)生殺傷腫瘤細胞的生物效應(yīng)。因此，抗MICA特異性抗體在腫瘤早期診斷、治療中可能具有更高的敏感性和療效，從而可實現(xiàn)腫瘤的“早診斷、早治療”。并且還能對其它治療方案的療效進行早期評估。 |
| 產(chǎn)品圖片 |
Sample:
Lane 1: Mouse Large intestine tissue lysates
Lane 2: Mouse Lung tissue lysates
Lane 3: Mouse Kidney tissue lysates
Lane 4: Mouse Liver tissue lysates
Primary: Anti-MICA (bs-0832R) at 1/1000 dilution
Secondary: IRDye800CW Goat Anti-Rabbit IgG at 1/20000 dilution
Predicted band size: 43 kDa
Observed band size: 60 kDa
Tissue/cell: mouse lung tissue; 4% Paraformaldehyde-fixed and paraffin-embedded;
Antigen retrieval: citrate buffer ( 0.01M, pH 6.0 ), Boiling bathing for 15min; Block endogenous peroxidase by 3% Hydrogen peroxide for 30min; Blocking buffer (normal goat serum,C-0005) at 37℃ for 20 min;
Incubation: Anti-MICA/MHC I a Polyclonal Antibody, Unconjugated(bs-0832R) 1:200, overnight at 4°C, followed by conjugation to the secondary antibody(SP-0023) and DAB(C-0010) staining
Tissue/cell: mouse intestine tissue; 4% Paraformaldehyde-fixed and paraffin-embedded;
Antigen retrieval: citrate buffer ( 0.01M, pH 6.0 ), Boiling bathing for 15min; Block endogenous peroxidase by 3% Hydrogen peroxide for 30min; Blocking buffer (normal goat serum,C-0005) at 37℃ for 20 min;
Incubation: Anti-MICA/MHC I a Polyclonal Antibody, Unconjugated(bs-0832R) 1:200, overnight at 4°C, followed by conjugation to the secondary antibody(SP-0023) and DAB(C-0010) staining
Tissue/cell: human lung carcinoma; 4% Paraformaldehyde-fixed and paraffin-embedded;
Antigen retrieval: citrate buffer ( 0.01M, pH 6.0 ), Boiling bathing for 15min; Block endogenous peroxidase by 3% Hydrogen peroxide for 30min; Blocking buffer (normal goat serum,C-0005) at 37℃ for 20 min;
Incubation: Anti-MICA/MHC I a Polyclonal Antibody, Unconjugated(bs-0832R) 1:200, overnight at 4°C, followed by conjugation to the secondary antibody(SP-0023) and DAB(C-0010) staining
Blank control (blue line): A431 (blue).
Primary Antibody (green line): Rabbit Anti-MICA antibody (bs-0832R)
Dilution: 1μg /10^6 cells;
Isotype Control Antibody (orange line): Rabbit IgG .
Secondary Antibody (white blue line): Goat anti-rabbit IgG-FITC
Dilution: 1μg /test.
Protocol
The cells were fixed with 2% paraformaldehyde (10 min) , then permeabilized with 90% ice-cold methanol for 30 min on ice. Cells stained with Primary Antibody for 30 min at room temperature. The cells were then incubated in 1 X PBS/2%BSA/10% goat serum to block non-specific protein-protein interactions followed by the antibody for 15 min at room temperature. The secondary antibody used for 40 min at room temperature. Acquisition of 20,000 events was performed.
|
| 1、抗體溶解方法 | |
| 2、抗體修復方式 | |
| 3、常用試劑的配制 | |
| 4、免疫組化操作步驟 | |
| 5、免疫組化問題解答 | |
| 6、Western Blotting 操作步驟 | |
| 7、Western Blotting 問題解答 | |
| 8、關(guān)于肽鏈的設(shè)計 | |
| 9、多肽的溶解與保存 | |
| 10、酶標抗體效價測定程序 | |
